نتایج جستجو برای: atomoxetine

تعداد نتایج: 721  

2009
Philip Hazell Katja Becker Eija A. Nikkanen Paula T. Trzepacz Yoko Tanaka Linda Tabas Deborah N. D’Souza Jennifer Witcher Amanda Long George Ponsler Ralf W. Dittmann

The purpose of this study was to examine whether atomoxetine plasma concentration predicts attention-deficit/hyperactivity disorder (ADHD) or oppositional defiant disorder (ODD) response. This post-hoc analysis assessed the relationship between atomoxetine plasma concentration and ADHD and ODD symptoms in patients (with ADHD and comorbid ODD) aged 6-12 years. Patients were randomly assigned to ...

Journal: :Journal of clinical psychopharmacology 2013
Todd M Durell Lenard A Adler Dave W Williams Ahmed Deldar James J McGough Paul E Glaser Richard L Rubin Teresa A Pigott Elias H Sarkis Bethany K Fox

BACKGROUND Attention-deficit/hyperactivity disorder (ADHD) is associated with significant impairment in multiple functional domains. This trial evaluated efficacy in ADHD symptoms and functional outcomes in young adults treated with atomoxetine. METHODS Young adults (18-30 years old) with ADHD were randomized to 12 weeks of double-blind treatment with atomoxetine (n = 220) or placebo (n = 225...

2016
Qing-Xian Hou Li Yu Shao-Qi Tian Cui-Jun Jiang Wen-Jiu Yang Zhi-Jie Wang

OBJECTIVES Spinal cord injury (SCI) often causes serious and irreversible neurological deficit leading to disability or impairment of normal physical activity. Atomoxetine, a selective norepinephrine transporter (NET) inhibitor has gained much attention in the field of the neurodevelopmental disorder, but its effect on SCI has not been evaluated. The present study has been undertaken to investi...

Journal: :Pediatrics 2016
Stephan Linden Regina Bussing Paul Kubilis Tobias Gerhard Richard Segal Jonathan J Shuster Almut G Winterstein

BACKGROUND Antidepressant effects on increased suicidality in children have raised public concern in recent years. Approved in 2002 for attention-deficit/hyperactivity disorder treatment, the selective noradrenalin-reuptake-inhibitor atomoxetine was initially investigated for the treatment of depression. In post-hoc analyses of clinical trial data, atomoxetine has been associated with an increa...

Journal: :British journal of clinical pharmacology 2007
Yi M Cui Choo H Teng Alan X Pan Eunice Yuen Kwee P Yeo Ying Zhou Xia Zhao Amanda J Long Mark E Bangs Stephen D Wise

AIMS To characterize atomoxetine pharmacokinetics, explore the effect of the homozygous CYP2D6*10 genotype on atomoxetine pharmacokinetics and evaluate the tolerability of atomoxetine, in healthy Chinese subjects. METHODS Twenty-four subjects, all CYP2D6 extensive metabolizers (EM), were randomized to receive atomoxetine (40 mg qd for 3 days, then 80 mg qd for 7 days) or matching placebo (2 :...

Journal: :The Journal of pharmacology and experimental therapeutics 2004
John-Michael Sauer Amanda J Long Barbara Ring Jennifer S Gillespie Nathan P Sanburn Karl A DeSante David Petullo Mark R VandenBranden Charles B Jensen Steven A Wrighton Brian P Smith Holly A Read Jennifer W Witcher

In the studies reported here, the ability of atomoxetine hydrochloride (Strattera) to inhibit or induce the metabolic capabilities of selected human isoforms of cytochrome P450 was evaluated. Initially, the potential of atomoxetine and its two metabolites, N-desmethylatomoxetine and 4-hydroxyatomoxetine, to inhibit the metabolism of probe substrates for CYP1A2, CYP2C9, CYP2D6, and CYP3A was eva...

Journal: :Journal of psychopharmacology 2007
Samuel R Chamberlain Ulrich Müller Sarah Cleary Trevor W Robbins Barbara J Sahakian

It has been proposed that acute hypothalamo-pituitary-adrenal (HPA) axis challenge using noradrenergic drugs may be of utility in assessing the functional integrity of central noradrenaline pathways. Atomoxetine (formerly tomoxetine) is a highly selective noradrenaline reuptake inhibitor, which has recently been licensed for the treatment of attention deficit hyperactivity disorder (ADHD). The ...

Journal: :Journal of psychopharmacology 2016
Chris Bushe Kathleen Day Victoria Reed Kristina Karlsdotter Lovisa Berggren Ashley Pitcher Foula Televantou Virginia Haynes

The lack of head-to-head clinical studies powered to compare atomoxetine and osmotic release oral system (OROS) methylphenidate necessitates treatment comparison by methods that include indirect evidence such as network meta-analysis (NMA). A NMA assessing the relative treatment effects of atomoxetine and OROS methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD) was co...

2009
Paul Hammerness Katherine McCarthy Elizabeth Mancuso Cassandra Gendron Daniel Geller

OBJECTIVE This review examines and summarizes the pharmacodynamic and pharmacokinetic properties, short- and longer-term efficacy, the moderating effect of comorbid disorders, as well as short- and long-term safety and tolerability of atomoxetine for the treatment of pediatric attention-deficit/hyperactivity disorder (ADHD). METHODS A systematic literature search was performed to review the e...

Journal: :Journal of child and adolescent psychopharmacology 2009
Christien G W de Jong Séverine Van De Voorde Herbert Roeyers Ruth Raymaekers Albert J Allen Simone Knijff Helene Verhelst Alfons H Temmink Leo M E Smit Rob Rodriques-Pereira Dirk Vandenberghe Inge van Welsen Liesbeth ter Schuren Mazim Al-Hakim Azad Amin Laurens Vlasveld Jaap Oosterlaan Joseph A Sergeant

OBJECTIVE The effects of a promising pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD), atomoxetine, were studied on executive functions in both ADHD and reading disorder (RD) because earlier research demonstrated an overlap in executive functioning deficits in both disorders. In addition, the effects of atomoxetine were explored on lexical decision. METHODS Sixtee...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید